Skip to main content
. 2024 May 14;51(9):2706–2732. doi: 10.1007/s00259-024-06696-9

Summary box nº 7

2-[18F]FDG PET/CT may play a role in monitoring treatment response in metastatic breast cancer (III-100%/C-85%)

2-[18F]FDG PET/CT may be particularly useful to assess bone metastases and enable early response to treatment evaluation (III-100%/C-100%)

The parenthesis contains the level of evidence—percentage of agreement/grade of recommendation—percentage of agreement.